Wednesday, Feb. 12

7:30-8:15 a.m.  Breakfast

8:30-8:45 a.m.  Welcome Remarks

     Hosts:
    Alzheimer’s Association, Harry Johns, MBA
    CurePSP, Larry Golbe, M.D.
    Rainwater Charitable Foundation, Patrick Brannelly, MBA

    Tau 2020 Co-Chairs:
    Diana Kerwin, M.D. and Peter Davies, Ph.D.

8:45-8:50 a.m.  First Plenary Introduction  Luc Buée, Ph.D.

8:50-9:20 a.m.  First Plenary
     Tau Research: History and Current Challenges  Jean-Pierre Brion, M.D., Ph.D.

Session 1:
9:20-9:40 a.m.  Tauopathies
     Tau and Neurodegeneration  Maria Grazia Spillantini, Ph.D.
9:40-10 a.m.   NPC/Other Secondary Tauopathies  Marc Patterson, M.D.

10-10:20 a.m.  Plenary and Panel Discussion
    Moderator: Irene Litvan, M.D.

10:20-10:45 a.m.  Break

Session 2:
10:45-11:05 a.m.  Tau Imaging
     Overview of Tau Imaging in Aging and AD  Keith Johnson, M.D.
11:05-11:25 a.m.  Tau Imaging in Non AD Tauopathies  Gil Rabinovici, M.D.
11:25-11:45 a.m.  Taupography: What Does It Tell Us?
     Tau Imaging in Anti-Tau Clinical Trials:
     [18F]GTP1 and the Semorinemab Biomarker Strategy  Gael Chetelat, M.D., Ph.D.

11:45 a.m.- 12:05 p.m.  Panel Discussion
    Moderator: Margaret Sutherland, Ph.D.

12:05-12:30 p.m.  Lunch and Poster Viewing
1:45-2:45 p.m.  **Lightning Poster Session**  
**Moderator:** Luc Buée, Ph.D.

2:45-2:50 p.m.  **Second Plenary Introduction**  
**Kathryn Bowles, Ph.D.**

2:50-3:20 p.m.  **Second Plenary**  
**What Genetic and Functional Studies Have Taught Us About the Role of MAPT in Neurodegeneration?**  
**Alison Goate, D. Phil.**

**Session 3: Genetics and Tauopathies**

3:20-3:40 p.m.  **Molecular Drivers of Primary Tauopathy**  
**Celeste Karch, Ph.D.**

3:40-4:05 p.m.  **Common Genetic Features in Primary Tauopathies**  
**John Hardy, Ph.D. & Huw Morris, M.D., Ph.D.**

4:05-4:25 p.m.  **Tau Contributions to Cognitive Decline in Neurodegenerative Diseases: Lessons From Colombian Families With Autosomal-Dominant Mutations**  
**Yakeel Quiroz, Ph.D.**

4:25-4:45 p.m.  **Plenary and Panel Discussion**  
**Moderator:** Jennifer Yokoyama, Ph.D.

4:45-5:10 p.m.  **Break**

5:10-5:25 p.m.  **Open AD: Open Science and Drug Discovery**  
**Aled Edwards, Ph.D.**

5:25-6:05 p.m.  **Panel and Debate**  
**Moderator:** Martin Citron, Ph.D.

**Propagation: Do We Have Sufficient Evidence? If Not, What Next?**

**Sufficient Evidence:** Marc Diamond, M.D. & Bess Frost, Ph.D.  
**Insufficient Evidence:** Karen Duff, Ph.D. & Brad Hyman, M.D., Ph.D.

6:05-6:35 p.m.  **Lightning Rounds for CurePSP**  
**Moderator:** Larry Golbe, M.D.

6:35-6:40 p.m.  **Close of Day One**  
**Maria Carrillo, Ph.D.**

6:45-9 p.m.  **Rainwater Prize Reception and Buffet**  
_All are welcome_
Thursday, Feb. 13

7:30-8:30 a.m. Breakfast

8:30-8:45 a.m. Open of Day Two Maria Carrillo, Ph.D.

Session 4: Molecular Mechanism for Therapeutic Approaches
8:45-9:05 a.m. Routing Tau Between and Within Cells Kenneth S. Kosik, M.D.
9:05-9:25 a.m. Exploring the Biodistribution of Tau-Targeting Sarah DeVos, Ph.D.
BBB-Penetrant Fusion Proteins in the CNS
9:25-9:45 a.m. Progress and Challenges Advancing the National Eliezer Masliah, M.D.
Plan to Address AD/ADRD
9:45-10:05 a.m. Discovery of Brain Penetrant PROTAC® Angela Cacace, Ph.D.
Degrader Molecules That Target Pathologic Tau

10:05-10:25 a.m. Panel Discussion
Moderator: Mike Hutton, Ph.D.

10:25-10:55 a.m. Break and Checkout

10:55-11:55 a.m. Second Lightning Poster Session
Moderator: Hui Zheng, Ph.D.

11:55 a.m.- Rainwater Prize Ceremony
12:55p.m. Keynote: Walter Koroshetz, M.D.
Short Talks: Patrick Hsu, Ph.D. and Michel Goedert, M.D., Ph.D.

12:55-2:10 p.m. Lunch and Poster Viewing

2:10-2:15 p.m. Third Plenary Introduction Diana Kerwin, M.D.

2:15-2:45 p.m. Third Plenary
Tau Therapeutics: Translational Challenges
in Moving From Bench to Bedside Adam Boxer, M.D., Ph.D.

Session 5: Tau Therapeutics
2:45-3:05 p.m. RNA-Targeted Therapy for Tauopathies Timothy Miller, M.D., Ph.D.
3:05-3:25 p.m. Initial Results From a Phase 2 Study of Mike Gold, M.D.
the Pan-Tau Antibody 8E12 in Patients
With Progressive Supranuclear Palsy
3:25-3:45 p.m. Targeting Tau In AD: A Trialist’s Perspective Cath Mummery, M.D., Ph.D.
3:45-4:05 p.m. Industry Perspective Philipp von Rosentiel, M.D.
4:05-4:25 p.m.  Plenary and Panel Discussion
Moderator: Howard Feldman, M.D.

4:25-4:40 p.m.  Break

4:40-5:15 p.m.  Panel Session
Early Stage Investment in Tau Therapeutics
Moderator: Patrick Brannelly, MBA
Stacie Weninger, Ph.D.
James Mutamba, Ph.D.
Dirk Beher, Ph.D.

5:15-5:30 p.m.  Closing Remarks
Co-Chairs:
Drs. Peter Davies and Diana Kerwin